Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Eli Lilly annonce que Mounjaro a atteint l'objectif principal d'un essai de phase III en démontrant sa non-infériorité face à ...

Le BPA de 6,31$ d’Eli Lilly au T2 2025 a dépassé les attentes de 12,88%. Le chiffre d’affaires a augmenté de 38% en ...

Eli Lilly and Company a publié les premiers résultats de l'étude SURPASS-CVOT, le tout premier essai de phase 3 comparant directement deux thérapies incrétines chez des adultes atteints ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...

Eli Lilly and Company is gearing up for its second quarter earnings report this Thursday, before the market opens. The ...

The complaint alleges the Indianapolis-based drugmaker offered illegal incentives to influence Texas providers to prescribe ...